PTC Therapeutics Announces Acquisition of ST-920 from Sangamo

What Happened
PTC Therapeutics announced it entered into an Asset Purchase Agreement on August 25, 2026 to acquire Sangamo’s assets primarily related to ST-920, a one-time AAV gene therapy candidate for Fabry disease. PTC agreed to pay $111 million upfront and up to $100 million in contingent milestone payments tied to FDA approvals. PTC was the winning bidder in a competitive bankruptcy auction of Sangamo’s assets; the sale is subject to Bankruptcy Court approval and other customary closing conditions.

Key Details

• Upfront purchase price: $111 million.
• Contingent milestones: up to $100 million total — $80 million upon FDA accelerated approval of a BLA for ST-920 based on Sangamo’s Phase 1/2 STAAR studies and related long‑term follow‑up, and $20 million upon full FDA approval.
• Conditions and timing: deal requires a Delaware Bankruptcy Court order, clearance of the Hart‑Scott‑Rodino waiting period, accuracy of representations and other customary closing conditions; bankruptcy hearing is scheduled for September 10, 2026.
• Termination/closing: either party may terminate under customary events; PTC or Sangamo can terminate if the acquisition hasn’t closed by October 15, 2026 (subject to exceptions). The purchase agreement’s reps and warranties do not survive closing and provide no indemnification for breaches.

Why It Matters
This transaction would add ST-920, a potentially one-time gene therapy for Fabry disease, to PTC’s pipeline and could create significant value if the program achieves FDA approvals tied to the milestone payments. The deal exposes PTC to near‑term cash outflow ($111M) and potential future payments (up to $100M) but remains conditional on bankruptcy court approval, antitrust review and other closing requirements. Investors should note the sale is through a bankruptcy process, the lack of post‑closing reps/indemnities, and that completion is not guaranteed.